Showing results (81-90 of 218) with videos related to

Sort By:
Pageof 22
Cancer|December 24, 2003
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phaseThomas B Sneed, Hagop M Kantarjian, Moshe Talpaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignanciesKaren W L Yee, Zhihong Zeng, Marina Konopleva, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 4, 2016
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML)Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi, et al.
Cancer|August 27, 2009
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemiaDeborah A Thomas, Hagop M Kantarjian, Wendy Stock, et al.
Leukemia & Lymphoma|October 14, 2014
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomesOhad Benjamini, Preetesh Jain, Long Trinh, et al.
The Journal of Chemical Physics|October 23, 2021
Graph network based deep learning of bandgapsXiang-Guo Li, Ben Blaiszik, Marcus Emory Schwarting, et al.
Cancer|January 19, 2012
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score systemWei-Gang Tong, Alfonso Quintás-Cardama, Tapan Kadia, et al.
The Lancet. Haematology|December 22, 2015
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trialsPreetesh Jain, Hagop Kantarjian, Mona Lisa Alattar, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 21, 2017
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive LeukemiaRita Assi, Hagop Kantarjian, Nicholas J Short, et al.
Cancer|December 12, 2003
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic dataHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Pageof 22